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http://www.biomedcentral.com/1471-2474/15/142RESEARCH ARTICLE Open AccessCardiovascular case fatality in rheumatoid arthritis
is decreasing; first prospective analysis of a current
low disease activity rheumatoid arthritis cohort
and review of the literature
Inger L Meek1,2*, Harald E Vonkeman1 and Mart AFJ van de Laar1Abstract
Background: Previous studies found increased case fatality after myocardial infarction and more frequent sudden
death in RA patients compared to non-RA subjects. The RA associated CV risk might be explained by the combined
effects of chronic systemic inflammation and increased lifestyle associated cardiovascular risk factors, and modified
by the use of medication such as non steroidal anti-inflammatory drugs, corticosteroids and disease modifying
anti-rheumatic drugs. Trends in case fatality rate in RA after the introduction of potent anti-inflammatory biologic
therapies and treat-to-target treatment strategies aiming at remission are not known. This study was performed to
examine the cardiovascular fatality rate in current low disease activity RA, and to evaluate trends in RA associated
CV case fatality over time.
Methods: Prospective study to determine the incidence of fatal and nonfatal CV events in 480 RA patients included
in the ACT-CVD cohort between February 2009 and December 2011. Patients with prior CV disease were excluded.
Cox regression analysis was performed to determine CV event risk and contributing risk factors over time. The results of
the cohort analysis were put into the context of a review of the literature to evaluate trends in RA associated CV fatality
rate over time.
Results: The study included 480 RA patients, 72.3% female with median disease duration of 4.2 years, 72.1% being in
clinical remission (Disease Activity Score in 28 joints). During a mean follow up of 2.9 years 29 patients (6%) experienced
a first CV event, 2 fatal and 27 non-fatal, corresponding to a 6.9% case fatality rate. Comparison with previous studies in
cohorts with successive enrolment periods shows a trend towards a decrease in CV case fatality in RA from 52.9% in 1998
to 6.9% in our study.
Conclusion: CV case fatality in current low disease activity RA is importantly lower than in previous studies, and a trend
towards decreasing CV fatality in RA is suggested.
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Rheumatoid arthritis (RA) is a chronic inflammatory dis-
ease involving multiple organ systems. RA is associated
with a decreased life expectancy, and premature death is
mainly due to accelerated atherosclerotic cardiovascular
(CV) disease [1-4]. Recent meta-analyses confirmed that
compared to the general population the overall increase
of both CV disease and death in RA is approximately
50% [5-7]. CV disease in RA is more severe and associated
with a worse prognosis, which was shown by studies in RA
cohorts with enrollment in the 1990s that found signifi-
cantly increased 30-day mortality after myocardial infarc-
tion and more frequent sudden death compared to non-RA
patients [8,9].
In the general population of high income countries the
patients’ prognosis after a CV event improved significantly
during the second half of the 20th century. Thirty to fifty
percent of the fall in general population CV mortality in
this period can be attributed to improved survival after a
CV event [10]. Analyses of time trends in RA associated
CV events show conflicting results and also recent studies
show increased CV events in RA patients compared to the
general population [6,11,12].
It is generally thought that RA associated CV risk is the
consequence of the combined effects of chronic systemic
inflammation and increased traditional CV risk factors,
and modified by the use non steroidal anti-inflammatory
drugs (NSAIDs), corticosteroids and disease modifying
anti-rheumatic drugs (DMARDs) [9,13-18]. After the intro-
duction of potent anti-inflammatory biologic therapies and
tight control treatment strategies into daily clinical care the
degree of systemic inflammation and severity of physical
disability have importantly improved. Therefore we per-
formed this study to examine if the high risk of death in
RA associated CV disease persists in tight controlled RA.
We evaluated the incidence of fatal and non-fatal CV
events in a cohort of established, currently low disease ac-
tivity RA patients between February 2009 and December
2012 and calculated CV case fatality rates. Subsequently we
put these results into the perspective of previous reports on
mortality in RA associated CV disease to explore trends in
RA associated CV case fatality over time.
Methods
Patients
The Arthritis Center Twente Cardiovascular Disease
(ACT-CVD) project was established in 2009. The method
of patient inclusion and baseline data collection in this
cohort has been described previously [19]. Briefly, in 2009
the Arthritis Center Twente (ACT) in Enschede, the
Netherlands, introduced a CV screening protocol as part
of routine daily clinical practice. The ACT-CVD database
contains the anonimised baseline demographics, CV risk
factors and rheumatic disease characteristics of all, bothprevalent and incident, participating patients. Individuals
are classified according to their clinical diagnosis as regis-
tered by experienced attending rheumatologists. Disease
duration was calculated as time from RA diagnosis until
the CV screening visit. At the ACT RA disease activity is
systematically measured by Disease Activity Score in 28
joints (DAS-28), RA remission being defined as a DAS-
28 ≤ 2.6 [20]. After inclusion in the database, patients are
followed up to a first CV event, death or censoring. Follow
up data on incident CV events and causes of death are ex-
tracted from the hospital electronic registration system
and are validated by medical chart review. For out of hos-
pital events and death, attending general practitioners re-
ceive periodic questionnaires and data is extracted from
the Dutch national registry of death certificates. Events are
considered to be of CV origin when the diagnosis was
confirmed by a cardiologist. For this study the data of all
RA patients without prior CV disease in the ACT-CVD
database that completed the CV screening protocol before
December 2011 were used (all RA 508; included 480).
The protocol for data collection and storage in the ACT-
CVD project was approved by the Arhtritis Center Twente
Institutional Review Board. Because the study contains data
from daily clinical practice the ethics committees deter-
mined, in accordance to Dutch law, that no approval was
requiered. Nontheless, patients were fully informed and
only the data of patients that gave informed consent were
entered into the ACT-CVD database.
Follow up and definition of CV events
All participants were followed up for the occurrence of
fatal and non-fatal CV events. The definition ‘CV event’
included (1) myocardial infarction; (2) coronary interven-
tion, i.e. percutaneous transluminal coronary angioplasty
(PTCA) or coronary artery bypass graft (CABG); (3) angina
pectoris; (4) acute heart failure; (5) cerebral vascular acci-
dent (CVA); (6) death due to cardiac causes; (7) sudden
death. Sudden death was considered a CV event because it
is generally from CV origin [21]. Duration of follow up was
calculated as the interval between inclusion and first CV
event or death, or censored at December 1st 2012, which-
ever came first.
Literature review
The Medline database was searched from its inception
to April 2013 for research articles and reviews published
in English studying CV disease in RA. The search terms
RA, cardiovascular, CVD, CVA, risk, co morbidity, mor-
tality, and death were used alone or in combination.
Reference lists of key publications were hand searched
for additional references. We selected peer reviewed arti-
cles (cohort studies and meta-analyses) that met the fol-
lowing criteria: (1) predefined RA criteria; (2) inclusion
of both male and female gender; (3) pre-specified CV
Table 1 Distributions of potential risk factors for occurrence
of cardiovascular events in RA patients at baseline
N = 480
Demographics
Sex (n,% female) 347 (72.3)
Age (mean, SD) 59.0 (13.0)
Traditional CV risk factors
Smoking, current (n,%) 114 (23.8)
Systolic blood pressure (mmHg, mean, SD) 144.0 (22.9)
Total cholesterol (mmol/L, SD) 5.3 (0.99)
LDL cholesterol (mmol/L, SD) 3.1 (0.83)
Triglycerides (mmol/L, SD) 1.3 (0.65)
Atherogenic index (mean, SD) 3.7 (1.1)
GlyHb (%, mean, SD) 5.8 (0.67)
SCORE 10-year estimated CV risk (%, SD)) 5.7 (4.9)
Inflammatory markers
ESR (mm/hr, mean, SD) 16.5 (14.9)
Hs CRP (mg/L, mean, SD) 7.0 (10.0)
RA disease characteristics
RA disease duration (years; median, 25th-75th percentile) 4.2 (1.5-11.3)
Seropositive (anti-CCP and/or IgMRF; n,%) 286 (63.3)
Erosions (n,%) 198 (42.2)
DAS 28 (mean, SD) 2.5 (1.2)
Remission (n,%) 223 (72.1)
Medication
DMARD (n,%) 350 (72.9)
MTX (n,%) 291 (60.6)
TNFα inhibitor (n,%) 105 (21.9)
NSAID (n,%) 177 (36.9)
Corticosteroids (n,%) 68 (14.2)
(RA: rheumatoid arthritis; CV: cardiovascular; SD: standard deviation; LDL: low
density lipoprotein; GlyHb: glycated hemoglobin; ESR: erythrocyte
sedimentation rate; Hs CRP: high sensitivity C-reactive protein; anti CCP: anti
cyclic citrullinated protein; IgM RF: IgM rheumatoid factor; DAS28: disease
activity score in 28 joints; DMARD: disease modifying antirheumatic drug;
MTX: methotrexate; TNF inhibitor: tumour necrosis factor α inhibitor; NSAID:
non steroidal anti inflammatory drug).
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information on RA disease duration before inclusion; (6)
information on events per patient year follow up. If data
from a single study were reported in more than one article
only the results from the most relevant publication were
included in the literature review. Because a recent meta-
analysis showed that inception cohorts were the only stud-
ies that did not find an increase of incident CV disease in
RA, we considered inception and non-inception cohorts
seperately [6].
Statistical analysis
Baseline characteristics of the RA cohort and incidence
of CV events were presented by appropriate descriptive
statistics. COX regression analysis was performed to deter-
mine CV event risk and contributing risk factors over time.
Statistical analyses were performed using IBM-SPSS statis-
tics software version 20.0.
Results
The ACT-CVD cohort included 1668 subjects, 508 with
a diagnosis of RA. From these, 28 were excluded because
of prior documented CV disease.
Baseline characteristics of RA patients
The present study included 480 RA patients. The patients’
mean age was 59.0 years and 72.3% were women. Median
RA disease duration was 4 years, 63% was IgM rheumatoid
factor and/or anti-CCP positive and 42% had erosive joint
disease. At inclusion in the ACT-CVD cohort, 390 (81%)
patients were using anti-inflammatory immunosuppressive
therapy; synthetic disease modifying anti-rheumatic drugs
(DMARDs, 72%), biologicals (in majority tumour necrosis
factor α inhibitor; any biological 23%, tumour necrosis fac-
tor α inhibitor 22%) or corticosteroids (14%), either alone
or in combination. Mean disease activity was low, DAS-28
2.5, 72% of patients being in clinical remission (Table 1).
Incident CV events
During the follow up period, 29 patients (6%) experi-
enced a first CV event. The mean follow up period was
2.9 years (SD 0.65) and total follow up of 1380 patient-
years, resulting in a CV event rate of 21/1000 patient-
years (95% CI 14.3-29.8). The different CV diagnoses
are listed in Table 2. There were 2 fatal CV events and
27 non-fatal. From the ten cases first presenting with
cardiac chest pain, three underwent a coronary inter-
vention procedure and three experienced a second CV
event during the total follow up period. None of the
patients that experienced a non-fatal CV event died
within the following 30 days, resulting in a 6.9% CV case
fatality rate (Table 3 and Additional file 1: Table S1).
COX regression analysis evaluating the relation between
traditional CV risk factors, inflammatory parameters, RAdisease duration, presence of IgM rheumatoid factor and/
or anti-CCP antibodies and use of anti-inflammatory
immunosuppressive therapy (i.e. methotrexate, non-
methotrexate DMARDs, tumour necrosis factor α inhibi-
tors or corticosteroids, which were considered seperately)
and the occurrence of CV events showed only statistically
significant independent risks of increasing systolic blood
pressure (HR 1.016, 95% CI 1.002-1.030) and use of antihy-
pertensive medications (HR 2.829, 95% CI 1.358-5.891)
(Additional file 2: Table S2). The use of methotrexate was
protective against incident first CV events (HR 3.436, 95%
CI 1.553-7.576).
Table 2 Distributions of cardiovascular events in RA patients according to disease duration (<6 months: incident
RA, ≥6 months: prevalent RA and IgM rheumatoid factor and/or anti-CCP positivity
Event type (n,%) RA (n = 480) Incident RA (n = 60) Prevalent RA (n = 240) Seronegative RA (n = 166) Seropositive RA (n = 286)
Myocardial infarction 2 (6.9) 1 (33.3) 1 (3.8) 1 (10.0) 1 (5.9)
Acute coronary syndrome 10 (34.5) 2 (66.6) 9 (34.6) 4 (40.0) 7 (41.2)
Acute heart failure 4 (13.8) 0 (0.0) 4 (15.4) 1 (10.0) 2 (11.8)
Coronary intervention 5 (17.2) 0 (0.0) 5 (17.2) 2 (20.0) 2 (11.8)
Cerebrovascular accident 5 (17.2) 0 (0.0) 5 (17.2) 1 (10.0) 4 (23.5)
Cardiac death 2 (6.9) 0 (0.0) 2 (7.7) 1 (10.0) 1 (5.9)
All 29 (100) 3 (100) 26 (100) 10 (100) 17 (100)
All, events/1000 py 21 18 21 20 21
(RA: rheumatoid arthritis; py: patient years).
Meek et al. BMC Musculoskeletal Disorders 2014, 15:142 Page 4 of 8
http://www.biomedcentral.com/1471-2474/15/142Literature review
We identified 24 studies and 2 meta-analyses evaluating
CV disease in RA, of which 15 studies reported patient-
years of follow up. Only nine studies evaluated composite
endpoints for CV disease and thus facilitated a comparison
with our own data. From these nine studies, four reported
on data from the same cohort. Only the article providing
data most relevant to our research was selected. One study
reported CV outcome after only one year of follow up,
which we considered to be short to evaluate CV mortality,
but was included because of it’s high methodological qual-
ity. Table 3 provides a summary of the characteristics and
results of the six selected studies, as well as our own data
[9,13,22-25]. There was considerable heterogeneity in
study characteristics such as cohort type, sample size, RA
disease duration and length of follow up. We distin-
guished two inception and five non-inception cohorts. The
studies showed no trend in CV event rate over time. How-
ever, there was a trend towards decline in percentage fatal
CV events within the composite CV disease outcome in
both inception and non-inception cohorts with successive
periods of enrolment.
Discussion
Summary of findings
This is the first study to search for trends in case fatality
in RA. The prospective analysis of the ACT-CVD cohort
shows that first CV events were common, even though
arthritis was tight controlled and overt inflammatory
activity was low. However, the observed percentage CV
deaths within the composite of CV events was import-
antly lower than observed in studies performed in older
cohorts with successive periods of enrolment, suggesting
a trend towards decreased case fatality.
Comparison with previous studies
Our finding of a composite CV event rate of 21/1000
patient-years does not differ importantly from earlier
clinic based non-inception cohorts evaluating CV dis-
ease incidence in RA. From the 1970s onwards manystudies have found increased CV disease in RA, which
showed some variation in their exact estimates for incident
RA associated CV morbidity and mortality depending on
factors such as sample size, cohort type, disease duration
and length of follow up [5,26,27]. In general, large commu-
nity based and inception cohort studies found lower CV
event risks than smaller clinic based studies or studies
including patients with established RA. Two recent meta-
analyses confirmed an approximately 50% overall increase
of both CV disease and death in RA compared to the gen-
eral population. RA associated CV disease incidence was
stable in the observation periods of the included studies
which ranged from 1955 to 2006 [5-7]. Increased CV dis-
ease in RA is thought to be caused by a combination of in-
creased traditional CV risk factors and disease specific
risks, probably most importantly chronic systemic inflam-
mation [28,29]. Different large cohort studies in the late
20th and early 21st century showed that inflammatory
disease activity and disability in RA could be importantly
improved by tight control treatment strategies using trad-
itional synthetic and/or novel biologic DMARDs [30-32].
These treatment strategies are currently implemented into
daily clinical care. However, an important decline in RA as-
sociated CV disease has not yet been obeserved [6,11,12].
In the general population CV disease is declining,
largely due to improved prevention by general health
and life style interventions. General population CV mor-
tality is declining even faster because of better treatment
of atherosclerotic vascular disease and improved event
survival [10,33]. As mentioned previously, studies on CV
disease in RA patients found increased CV event inci-
dence, but some studies also observed that RA patients
had a worse prognosis with more frequent fatality of CV
events. In our cohort the proportion fatal among the
composite of CV events was low. Comparison of our re-
sults with previous studies in non-inception cohorts with
successive periods of enrolment suggests a trend of de-
creasing CV case fatality in RA from 1996 until now
(28.6% vs. 6.9% fatal CV events, Table 3). This finding is
supported by the results of two studies in inception
Table 3 Characteristics of the 6 studies included in the literature review
Reference Country Enrolment
period
Mean
follow
up
(years)
Sample
type
Inception
cohort
RA
definition
%
female
Mean age
at entry
Previous
CVD
excluded
CVD
included
Outcome
ascertainment
N Person-
years
at risk
CV
events
(n)
CV events/
1000 person-
years
Fatal
CV
events
(%)
Del
Rincon,
2001 [13]
USA 1996 0.9 Clinic
based
No ACR 1987 62.3 56* Yes MI, CVA,
CV death
Medical record 236 204 7 34.3 28.6
Assous,
2007 [23]
France 1998-1999 5.4 Clinic
based
No ACR 1987 83.8 55 Yes MI, CVA,
CV death
Medical record 239 NAV 17 13 52.9
Solomon,
2006 [23]
USA 1999-2003 2.8 Population
based
No ICD code 71.1 NAV No MI, CVA,
CV death
ICD code 25,385 70,612 1,042 14.8 41.2
Peters,
2009 [24]
Netherlands 2001-2002 2.7 Clinic
based
No ACR 1987 65 63 Yes Coronary
disease,
CVA, CV
and
sudden
death
Medical record 272 729 19 26.1 12.9**
Meek,
2013***
[19]
Netherlands 2009-2011 2.9 Clinic
based
No Clinical
diagnosis
72.3 59 Yes Coronary
disease,
CVA, CV
and
sudden
death
Medical record 480 1380 29 21 6.9
Maradit-
Kremers,
2005 [9]
USA 1955-1995 14.7 Population
based
Yes ACR 1987 73 58 Yes MI, CABG,
PTCA, AP,
CV and
sudden
death
Medical record 603 8,672 109 13.0 23.8
Holmqvist,
2010 [25]
Sweden 1995-2006 4.1 Population
based
Yes ACR 1987 71.0 56.9 Yes MI, AP,
CABG,
PTCA, CV
death
Hospital
discharge
register
7,469 33,436 341 10.2 11.1
Studies are placed in order of cohort type (non-inception vs inception) and enrolment period. RA: rheumatoid arthritis; CVD: cardiovascular disease; MI: myocardial infarction; CVA: cerebrovascular incident; CV:
cardiovascular; CABG: coronary artery bypass graft; PTCA: percutaneous transluminal coronary angioplasty; AP: angina pectoris; NAV: not available. * Median. ** non-published data received from the authors. ***data
from the ACT-CVD cohort presented in htis article.
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successive enrolment periods but a lower proportion
fatal CV events between 1995–2006 compared to 1955–
1995 (11.1% vs. 23.8% fatal CV events, Table 3).
A relative decrease in fatal CV events in RA over the last
decades could be explained in different ways. On the one
hand, reduction of the RA specific risk factors can result in
a more benign course of RA associated CV disease and a
CV event prognosis more similar to the general population.
As mentioned previously, systemic inflammatory activity is
thought to be the most important RA specific risk factor
[28,29]. The majority of the patients in our cohort were
treated following a tight control strategy targeted at remis-
sion induction that has been shown to establish stable low
disease activity [34]. Also corticosteroid usage, associated
with increased CV disease in RA, was very low in our
cohort [15]. On the other hand, one might speculate that
because of increased awareness, RA associated CV disease
is now recognised at an earlier stage. In 2009 the EULAR
published the first recommendations for CV risk manage-
ment in RA. However, recent research has shown that
implementation of these recommendations into clinical
practice has not yet been widely established [35-37]. Our
cohort was initiated before the publication of the EULAR
recommendations, and in the ACT CV risk factor screen-
ing was not followed by a per protocol intensified CV risk
management.
Strengths and limitations
This study has several limitations. The relatively short dur-
ation of follow up of our cohort does not allow evaluation
of trends in CV event rate over time within the same popu-
lation, and it may also cause an underestimation of fatal
CV events. In a non-inception cohort such as the ACT-
CVD cohort this will probably be of lesser importance,
as CV disease in RA is thought to develop and accumulate
with longer disease duration. Also, the literature review in-
cluded two other non-inception studies with similar follow
up duration in different periods of enrolment, which allows
comparison of results. As mentioned previously, studies on
RA vary importantly in study population characteristics,
and this was also true in our comparison to the literature.
The incidence of CV disease may vary with ethnicity and
social status, which variables were not registered in our
database. The ACT is situated in a rural region of the
Netherlands, where the vast majority of the population is of
Caucasian origin, and access to healthcare is guaranteed by
the national healthcare insurance system. Only one of the
studies included in the literature review mentioned ethni-
city of the study population, which was over 90% white
race, and no study described social status characteristics.
The proportion seropositive RA, a possible indicator of
more severe phenotype, varied between studies and was
lowest in our cohort. This limitation may account in partfor our findings, as our patients may in fact have had milder
disease and thus a lower overall inflammatory burden; how-
ever, our cohort does not differ markedly from others re-
cently reported on tight control treatment in RA [30,32].
Because we identified only a limited number of studies that
reported composite and fatal CV outcome parameters
which allowed comparison with our own data, selection
bias should be considered when interpreting the literature
review, but we were able to include data from cohorts that
contributed importantly to the present knowledge on RA
associated CV disease. Finally, our study was explorative,
and cannot provide definite conlusions because we do not
have control CV event data. The possible trend of decreas-
ing CV case fatality in RA should be confirmed by further
research comparing CV event and case fatality rates in RA
patients to those in the general population in the same re-
gion and time period.
Conclusion
In this study in a current cohort of low disease activity
RA the observed percentage CV deaths within the compos-
ite of CV events was importantly lower than in previous
studies with successive periods of enrolment. A trend to-
wards decreasing CV fatality in RA is suggested and should
be re-evaluated in cohort studies with control populations
and longer follow up.
Additional files
Additional file 1: Table S1. Distributions of potential risk factors for
occurrence of cardiovascular events in RA patients at baseline, according
to RA duration (<6 months: incident RA; ≥6 months: prevalent RA). (RA:
rheumatoid arthritis; CV: cardiovascular; SD: standard deviation; LDL: low
density lipoprotein; GlyHb: glycated hemoglobin; ESR: erythrocyte
sedimentation rate; Hs CRP: high sensitivity C-reactive protein; anti CCP:
anti cyclic citrullinated protein; IgM RF: IgM rheumatoid factor; DAS28:
disease activity score in 28 joints; DMARD: disease modifying antirheumatic
drug; MTX: methotrexate; TNF inhibitor: tumour necrosis factor α inhibitor;
NSAID: non steroidal anti inflammatory drug). *p<0.05 seronegative vs
seropositive.
Additional file 2: Table S2. Distributions of potential risk factors for
occurrence of cardiovascular events in RA patients at baseline, according
to presence of IgM and/or anti-CCP antibodies. (RA: rheumatoid arthritis;
CV: cardiovascular; SD: standard deviation; LDL: low density lipoprotein;
GlyHb: glycated hemoglobin; ESR: erythrocyte sedimentation rate; Hs CRP:
high sensitivity C-reactive protein; anti CCP: anti cyclic citrullinated pro-
tein; IgM RF: IgM rheumatoid factor; DAS28: disease activity score in 28
joints; DMARD: disease modifying antirheumatic drug; MTX: methotrexate;
TNF inhibitor: tumour necrosis factor α inhibitor; NSAID: non steroidal anti
inflammatory drug). *p<0.05 seronegative vs seropositive.
Abbreviations
RA: Rheumatoid arthritis; CV: Cardiovascular; ACT-CVD: Arthritis Center
Twente CardioVascular Disease cohort; NSAIDs: Non-steroidal anti-
inflammatory drugs; DMARDs: Disease modifying anti-rheumatic drugs;
ACT: Arthritis Center Twente; DAS-28: Disease activity score in 28 joints;
PTCA: Percutaneous transluminal coronary angioplasty; CABG: Coronary
artery bypass graft; CVA: Cerebrovascular accident; CVD: Cardiovascular
disease; Anti-CCP: Anti cyclic citrullinated pepside antibody; SD: Standard
deviation; LDL: Low density lipoprotein; GlyHb: Glycated hemoglobin;
ESR: Erythrocyte sedimantation rate; Hs CRP: High sensitivity C-reactive
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